Clinical Trial Update: Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating ursodeoxycholic acid as a neuroprotective adjuvant in rhegmatogenous retinal detachment surgery is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: Hopital Foch | Conditions: Retinal Detachment | Phase 3 | Status: RECRUITING